2018
DOI: 10.1016/s2213-2600(18)30235-2
|View full text |Cite
|
Sign up to set email alerts
|

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

Abstract: SummaryBackground Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

10
153
1
7

Year Published

2018
2018
2022
2022

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 202 publications
(172 citation statements)
references
References 16 publications
(17 reference statements)
10
153
1
7
Order By: Relevance
“…Since 2013, BDQ has been recommended for the treatment of multidrug‐resistant (MDR) TB by the World Health Organization and is currently being implemented at the programme level . Emerging results from the use of BDQ around the world show that sputum culture conversion rates are improved when BDQ is added to a background regimen …”
Section: Introductionmentioning
confidence: 99%
“…Since 2013, BDQ has been recommended for the treatment of multidrug‐resistant (MDR) TB by the World Health Organization and is currently being implemented at the programme level . Emerging results from the use of BDQ around the world show that sputum culture conversion rates are improved when BDQ is added to a background regimen …”
Section: Introductionmentioning
confidence: 99%
“…This was despite the investigators within the study not attributing the increased number of deaths to the use of Bdq. In support of this, a large retrospective cohort study of individuals with MDR/XDR-TB in South Africa, found that adding Bdq to a treatment regimen was associated with a reduction in all-cause patient mortality (Schnippel et al, 2018). Having a pill-only regimen would be a considerable additional advantage for patients, when taken together with the reduced treatment time.…”
Section: Stream Trial Stagementioning
confidence: 80%
“…As a result, the number of patients eligible to receive bedaquiline-containing regimens would significantly increase. Encouraging results from studies currently underway on the use of bedaquiline in all-oral, shorter-course regimens for the treatment of rifampicin-resistant TB could result in an even greater use of bedaquiline in TB control programmes globally (2,3). However, solid surveillance of drug-resistance is needed to monitor the emergence of resistance to bedaquiline in patients during therapy.…”
Section: Manuscriptmentioning
confidence: 99%